Conference Correspondent

Checkpoint Inhibitors in Lymphoma: A New Universe

Immunotherapy is generating great excitement in melanoma and non–small cell lung cancer (NSCLC). FDA approvals of checkpoint inhibitors in these tumor types, as well as encouraging preliminary results in other solid tumors, have paved the way for studying them in hematologic cancers.Philippe Armand, MD, Dana-Farber Cancer Institute, Boston, MA, discussed [ Read More ]

CAR T-Cell Therapy Highly Active in Various Hematologic Malignancies

CAR T cells demonstrated consistent activity in advanced hematologic malignancies evaluated in multiple small clinical trials reported at the meeting.Disease remission persisting for as long as 36 months occurred in 8 of the first 20 patients treated at the National Cancer Institute. The 40% overall response rate included 4 of [ Read More ]

Venetoclax: Strong Showing in CLL

Venetoclax, an oral, investigational, small molecule Bcl-2 inhibitor, achieved excellent and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (RR CLL). All patients in the trial harbored a 17p deletion, signaling poor prognosis.In a pivotal phase 2 trial reported at the meeting, nearly 80% of patients with high-risk RR [ Read More ]

Another Study Shows Benefit with a Pediatric Regimen in Young Adults with ALL

A pediatric regimen achieves superior outcomes compared with adult regimens in adolescents and young adults with acute lymphoblastic leukemia (ALL). Several studies have already shown this outcome, and a multicenter phase 2 study presented at the meeting adds further confirmatory evidence in support of this approach. The multicenter phase 2 [ Read More ]

Personalizing Therapeutics for Melanoma in the 21st Century

Advocating for biomarker-driven “smart” trials, making the case for patient selection for specific drugs, and the concept of rational combinations as potential targeted therapies in order to improve the efficacy of clinical trials were topics of an insightful presentation delivered by Dr Aleksandar Sekulic on behalf of Dr Pat LoRusso [ Read More ]

ALK-Targeted Agent Has High Activity in Some Childhood Cancers

In a preliminary phase 1 study, the targeted drug crizotinib (Xalkori) stabilized disease progression and, in some children, eradicated cancer cells in relapsed, refractory, aggressive childhood cancers that are likely to harbor genetic abnormalities in the ALK gene: anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and aggressive neuroblastoma. [ Read More ]

Neoadjuvant Abiraterone Potential Approach

Abiraterone, which is FDA-approved for the treatment of advanced prostate cancer, had encouraging results in one of the first studies to evaluate use of this targeted agent earlier in the course of disease. Targeted hormonal therapy with abiraterone plus leuprolide was able to eradicate cancer in the prostate in some [ Read More ]

Dual Targeting in Advanced Melanoma Encouraging

Hitting 2 targets may be better than 1 in advanced melanoma, suggests a preliminary trial of combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. Combined targeting with these 2 agents achieved tumor regression with a lower incidence of skin side effects compared with published data on [ Read More ]

What Oncologists Need to Know About 7 New Agents

Oncologists should understand the characteristics of 7 emerging drugs and biologics that should improve patient care. At the 2012 Pharmacy Program held during the 17th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood, Florida, Van Anh Trinh, PharmD, of the University of Texas MD Anderson Cancer Center, [ Read More ]

New Agents Prove Potent Against HER2-Positive Breast Cancer

Trastuzumab changed the course of HER2-positive breast cancer, and future anti-HER2 therapies may have an even greater impact, said Kristine Abueg, RN, MSN, OCN, clinical research nurse at Kaiser Permanente in Roseville, California, who discussed “What’s New in HER2?” at the 37th Annual Congress of the Oncology Nursing Society. In [ Read More ]

Sign me up!